empagliflozin

Home
Ligands
empagliflozin

Ligand id: 4754

Name: empagliflozin

View more information in the IUPHAR Pharmacology Education Project: empagliflozin

Structure and Physico-chemical Properties

2D Structure

Calculated Physico-chemical Properties
Hydrogen bond acceptors	6
Hydrogen bond donors	4
Rotatable bonds	6
Topological polar surface area	108.61
Molecular weight	450.14
XLogP	2.9
No. Lipinski's rules broken	0

Molecular properties generated using the CDK

Classification
Compound class	Natural product or derivative
Approved drug?	Yes (FDA & EMA (2014))

IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

IUPAC Name

(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol

International Nonproprietary Names
INN number	INN
9398	empagliflozin

Synonyms
BI 10773

Synonyms

BI 10773

Database Links
CAS Registry No.	864070-44-0 (source: Scifinder)
ChEBI	CHEBI:82720
ChEMBL Ligand	CHEMBL2107830
GtoPdb PubChem SID	178101464
PubChem CID	11949646
Search Google for chemical match using the InChIKey	OBWASQILIWPZMG-QZMOQZSNSA-N
Search Google for chemicals with the same backbone	OBWASQILIWPZMG
Search PubMed clinical trials	empagliflozin
Search PubMed titles	empagliflozin
Search PubMed titles/abstracts	empagliflozin
Search UniChem for chemical match using the InChIKey	OBWASQILIWPZMG-QZMOQZSNSA-N
Search UniChem for chemicals with the same backbone	OBWASQILIWPZMG
Wikipedia	Empagliflozin

Comments
Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar. It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.

Comments

Empagliflozin is a member of the 'gliflozin' class of drugs which inhibit reabsorption of glucose in the kidney to lower blood sugar.
It is the first glucose-lowering, antidiabetes therapy to be granted approval to reduce the risk of cardiovascular (CV) death in type 2 diabetes patients with CV disease.